Table of contents
- Trial overview
- Conditions being studied
- Trial phases and patient groups
- Main outcomes and endpoints
- Study designs and comparators
- What these trials mean for patients
Trial overview
The trial data shows Aripiprazole being studied in several interventional trials across different mental health conditions.[1] These studies include completed, authorised, and later-phase trials, which means the research is at different stages of development and use.[1]
Some studies use Aripiprazole alone, while others compare it with other medicines or use it as part of a broader treatment plan.[1] The main purpose of these trials is to see how well treatment strategies work in specific patient groups and what outcomes improve over time.[1]
Conditions being studied
The trials cover a wide range of conditions, including substance-induced psychosis, schizophrenia, schizophrenia spectrum disorders, autism spectrum disorder, Tourette disorder, refractory major depression disorder, and behaviors that challenge in intellectual disabilities.[1]
One trial studies juvenile patients with substance-induced psychosis and cannabis use disorder, with Aripiprazole listed among the background antipsychotic treatments.[1] Other trials focus on people with a first episode of psychosis, patients in remission after a first psychotic episode, elderly people with refractory major depression disorder, and adults with Tourette disorder.[1]
There is also a trial in people with autism spectrum disorder that compares treatment approaches using Aripiprazole or risperidone, with a focus on weight-related change.[1]
Trial phases and patient groups
The trials include Phase 1, Phase 2, Phase 3, and Phase 4 research.[1] This shows that Aripiprazole is being studied from early testing through later studies in routine care.[1]
Several Phase 3 trials include larger groups, such as patients with schizophrenia spectrum disorders, early psychosis, autism spectrum disorder, and treatment-resistant depression in older adults.[1] Smaller studies include a Phase 2 Tourette disorder trial and a Phase 1 study in first episode psychosis.[1]
The target populations are varied. They include juvenile patients, children and adolescents, adults, and elderly participants, depending on the study question.[1]
Main outcomes and endpoints
The main outcomes are different from trial to trial, but many focus on symptom change, functioning, or treatment response.[1] In the HAMLETT study, the primary outcome is long-term social recovery, measured with the World Health Organization Disability Assessment Schedule.[1]
In the SchizOMICS study, researchers want to identify biomarkers that can predict response to Aripiprazole or paliperidone after 3 months, and they also assess psychotic symptoms using PANSS and CGI-S scales.[1] In another schizophrenia-spectrum study, the main endpoint is functional remission, defined as a PSP score above 70 at 24 months.[1]
Other endpoints include change in body mass index z-scores after 6 months in children with autism spectrum disorder, correlation between receptor binding and impulsivity scores in Tourette disorder, change in cognitive functioning in early psychosis, and reduction of negative symptoms in first episode psychosis.[1]
In the elderly depression study, the main outcome is clinical response at 8 weeks, including remission of depressive symptoms and adequate clinical response based on MADRS and CGI severity scores.[1] In the trial on behaviors that challenge, the main outcome is change over time in ABC-I scores, which measure irritability-related behavior.[1]
Study designs and comparators
Most of the studies are interventional, meaning the research team assigns the treatment or treatment strategy.[1] Some trials compare Aripiprazole with other antipsychotic medicines, while others compare continuation with dose reduction or discontinuation of antipsychotic treatment.[1]
Several studies use a randomized or controlled design. For example, one trial compares Aripiprazole with risperidone in children with autism spectrum disorder, and another compares Aripiprazole with esketamine plus an antidepressant in elderly patients with refractory depression.[1]
In the AMEND study, Aripiprazole is part of the background treatment in a randomized, double-blind, placebo-controlled study that tests add-on memantine for first episode psychosis.[1] In the substance-induced psychosis study, Aripiprazole is listed among the antipsychotic options given alongside CBD or placebo.[1]
What these trials mean for patients
These studies show that Aripiprazole is being tested in very different patient groups, not just in one diagnosis.[1] The trials are asking practical questions such as whether symptoms improve, whether function and recovery improve, and whether treatment strategies should be continued, reduced, or changed.[1]
Some trials are focused on early illness, such as first episode psychosis or early psychosis, while others focus on long-term management or special groups like older adults and children.[1] This makes the research useful for understanding where Aripiprazole fits in different treatment plans and patient needs.[1]
